Drug Trial Radar · NCT05723549
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
Last checked: Nov 20, 2026Latest source record: Sep 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Feb 2, 2023
Primary completion
Mar 20, 2023
Study completion Mar 20, 2023
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.
Conditions
- Healthy
Interventions
HCP1803-3Drug
Take it once per period
RLD2002Drug
Take it once per period
HCP1904-1Drug
Take it once per period
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 0~144hours
- AUC lastTime frame: 0~144hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.